Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Oramed Pharmaceuticals Inc Market Cap
The Oramed Pharmaceuticals Inc (ORMP) share price is expected to increase by 36.55% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered ORMP. Price targets range from $3.25 at the low end to $3.25 at the high end. The current analyst consensus for ORMP is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assigned ORMP 2 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Oramed Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ORMP. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ORMP.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Neutral | Reiterates | Sep 9, 2024 | |
| Raghuram Selvaraju HC Wainwright & Co. | Neutral | Reiterates | May 20, 2024 | |
| Edward Nash Canaccord Genuity | Hold | $2 | Maintains | May 17, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Neutral | Downgrade | Jan 17, 2023 | |
| Edward Nash Canaccord Genuity | Hold | Downgrade | Jan 12, 2023 | |
| Nathan Weinstein Aegis Capital | Buy | $30 | Maintains | May 16, 2022 |
Cantor Fitzgerald | Overweight | Initiates | Feb 18, 2022 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $32 | Maintains | Nov 30, 2021 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $32 | Maintains | Nov 29, 2021 |
| Nathan Weinstein Aegis Capital | Buy | $35 | Maintains | Nov 2, 2021 |
Canaccord Genuity | Buy | $30 | Maintains | Jul 29, 2021 |
| Nathan Weinstein Aegis Capital | Buy | $20 | Maintains | Jun 8, 2021 |
Canaccord Genuity | Buy | Initiates | Apr 20, 2021 | |
National Securities Corporation | Buy | Initiates | Feb 9, 2021 | |
| Nathan Weinstein Aegis Capital | Buy | $12 | Maintains | Jan 27, 2021 |
HC Wainwright & Co. | Buy | $17 | Reiterates | Jul 13, 2020 |
HC Wainwright & Co. | Buy | $16 | Maintains | Jun 22, 2020 |
Ladenburg Thalmann | Buy | Initiates | Sep 11, 2019 | |
FBR Capital | Outperform | Initiates | Nov 19, 2015 | |
H.C. Wainwright | Buy | Initiates | Oct 1, 2015 |
When did it IPO
2007
Staff Count
0
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Nadav Kidron Esq.
Market Cap
$96.8M
In 2023, ORMP generated $1.3M in revenue, which was a decrease of -50.43% from the previous year. This can be seen as a signal that ORMP's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 08 Jul 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Micro-cap stocks, with market capitalizations between $50 million and $300 million, often overlap with penny stocks, which are typically considered higher risk investments.
Why It Matters - Micro-cap stocks, overlapping with penny stocks, offer high risk and potential for substantial returns, attracting investors seeking growth in smaller companies.
Wed, 26 Jun 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Oramed Pharmaceuticals' Board has approved a $20 million stock repurchase plan, allowing buybacks over the next 12 months based on market conditions and company discretion.
Why It Matters - Oramed's $20 million stock repurchase plan signals confidence in its value, potentially boosting share prices and indicating management's belief in the company's growth prospects.
Wed, 26 Jun 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Oramed Pharmaceuticals announced a $20 million stock repurchase program and provided a shareholder update on its oral drug delivery developments and a trial in collaboration with HTIT.
Why It Matters - Oramed's $20 million stock repurchase program signals confidence in its value, potentially boosting share prices and indicating positive expectations for its oral insulin trial.
Thu, 21 Sep 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Oramed Pharmaceuticals has secured an 18-month loan from Scilex at SOFR plus 8.5% interest and received warrants for 17 million shares of Scilex. This replaces a prior agreement with Sorrento Therapeutics.
Why It Matters - The loan's high interest rate and the issuance of warrants indicate potential dilution for existing shareholders of Scilex, affecting stock valuation and future capital structure.
Wed, 02 Aug 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Oramed Pharmaceuticals and Hefei Tianhui Biotech are forming a joint venture for oral drug delivery, with Oramed investing $10 million and HTIT $60 million, aiming to advance oral insulin registration.
Why It Matters - The joint venture between Oramed and HTIT, focusing on oral insulin technology, could enhance market potential, drive revenue growth, and impact stock performance positively.
Tue, 20 Jun 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Oramed Pharmaceuticals will present at the American Diabetes Association's 83rd Scientific Sessions on June 23-26, 2023, discussing Phase 2 trial data for oral insulin in treating NASH and Type 2 Diabetes.
Why It Matters - Oramed's presentation at a major conference highlights potential breakthroughs in diabetes and liver disease treatments, which could enhance investor confidence and affect stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
